Survivin and aven: two distinct antiapoptotic signals in acute leukemias
Survivin and aven: two distinct antiapoptotic signals in acute leukemias
复制标题
DOI：
10.1093/annonc/mdg277
复制
发表时间：
2003-07-01
影响因子：
50.5
通讯作者：
Burgut, R
中科院分区：
文献类型：
--
作者：
Paydas, S;Tanriverdi, K;Burgut, R
背景：抗凋亡信号在恶性肿瘤的发生、进展和预后中发挥着重要作用。本研究的目的是确定急性白血病中两种不同的抗凋亡信号——生存素和燕麦，并将它们与临床和血液学结果以及治疗反应进行比较。采用实时定量PCR，在信使（m）RNA水平检测survivin和aven。患者和方法：以65例急性白血病患者[37例急性髓细胞白血病（AML）和28例急性淋巴细胞白血病（ALL）]作为研究组，10例健康受试者作为对照组。结果：Survivin在0.0至0.829之间拷贝数/细胞（中位数0.0721，平均值0.5424301909+/-0.139799488589）和aven在0.0和0.853拷贝数/细胞之间（中位数0.0124，平均值0.070335542+/-0.1524685709）。我们发现 survivin 和 aven 之间存在重要关联 (P=0.000)。研究组的 survivin 和 aven 均高于对照组（P 分别为 0.001 和 0.035）。当我们将survivin和aven与其他临床和血液学参数进行比较时，发现survivin与髓外受累（P=0.033）、survivin与碱性磷酸酶（P=0.06）、白细胞（WBC）计数和乳酸脱氢酶（LDH）（P=0.000）、WBC计数与尿酸（P=0.074）、血红蛋白水平和血红蛋白水平之间存在重要关联。 LDH (P=0.072)、LDH 和尿酸 (P=0.057)、CD7 表达和 survivin (P=0.097)、CD34 表达和 aven (P=0.058)。根据存活素和 aven 水平评估对治疗的反应。与完全缓解者相比，难治性患者的生存素水平较低（P=0.085）。复发患者的Aven水平高于未复发患者（P=0.04）。 survivin或aven与体能状态、淋巴结肿大或器官肿大之间没有重要的相关性。 结论：survivin和aven都是急性白血病中重要的抗凋亡信号，髓外受累、CD7表达和CD34表达（急性白血病中重要的不良预后指标）之间的关联提示survivin和/或aven可能是急性白血病中新的预后指标。对更多患者进行进一步研究将提供更多信息。
Background: Antiapoptotic signals are important in the development, progression and prognosis of malignant tumors. The aim of this study was to determine the two distinct antiapoptotic signals-survivin and aven-in acute leukemias and compare them with clinical and hematological findings and response to therapy. Real-time quantitative PCR was used and survivin and aven were detected at the messenger (m)RNA level.Patients and methods: Sixty-five patients with acute leukemia [37 with acute myeloblastic leukemia (AML) and 28 with acute lymphoblastic leukemia (ALL)] were used as the study group and 10 healthy subjects were used as the control group.Results: Survivin was between 0.0 and 0.829 copy number/cell (median 0.0721, mean 0.5424301909+/-0.139799488589) and aven was between 0.0 and 0.853 copy number/cell (median 0.0124, mean 0.070335542+/-0.1524685709). We found an important association between survivin and aven (P=0.000). Both survivin and aven were higher in the study group than in the controls (P=0.001 and 0.035, respectively). When we compared survivin and aven with other clinical and hematological parameters, there was an important association between survivin and extramedullary involvement (P=0.033), survivin and alkaline phosphatase (P=0.06), white blood cell (WBC) count and lactate dehydrogenase (LDH) (P=0.000), WBC count and uric acid (P=0.074), hemoglobin level and LDH (P=0.072), LDH and uric acid (P=0.057), CD7 expression and survivin (P=0.097), and CD34 expression and aven (P=0.058). Response to therapy was evaluated according to the survivin and aven levels. Survivin level was lower in refractory patients as compared with complete responders (P=0.085). Aven level was higher in patients with relapse as compared with non-relapse patients (P=0.04). There was no important association between survivin or aven and performance status, lymphadenopathy or organomegaly.Conclusions: Both survivin and aven are important antiapoptotic signals in acute leukemias, and the association between extramedullary involvement, CD7 expression and CD34 expression, which are important poor prognostic indicators in acute leukemias, suggests that survivin and/or aven may be novel prognostic indicators in acute leukemias. Further studies with a higher number of patients will be more informative.